Engineered Protein Breakdown Supercharges Drug-Free Selection of High-Producing CHO Cells

One of the most persistent bottlenecks in biopharmaceutical manufacturing is a deceptively simple question: how do you find the rare cells, among millions, that can churn out enormous quantities of a therapeutic protein? A research team at Inha University in Incheon, South Korea, has now offered an elegant answer that works not by adding more drugs or more genes, but by deliberately destabilizing a single protein that cells need to survive. In a study published in Applied Microbiology and Biotechnology, Hagyeong Kim, Jong Uk Park, Jaein Ha, and Jong Youn Baik describe how they engineered degradable variants of glutamine synthetase, an enzyme long used as a selection marker in Chinese hamster ovary cells, and used the resulting selection pressure to isolate cell pools with dramatically improved productivity. Their top-performing pool produced 870 milligrams per liter of Etanercept, a widely prescribed fusion protein drug, in simple shake-flask batch culture, and it did so without any chemical selection agent in the medium.

To appreciate why this matters, it helps to understand how the glutamine synthetase system has worked for decades. Chinese hamster ovary cells, or CHO cells, are the workhorses of the biotechnology industry, producing the majority of recombinant therapeutic proteins on the market, from monoclonal antibodies to enzyme replacement therapies. When researchers want a CHO cell line to make a therapeutic protein, they typically link the gene for that protein to the gene for glutamine synthetase, an enzyme that allows cells to synthesize glutamine, an amino acid essential for growth. When the cells are grown in medium lacking glutamine and containing methionine sulfoximine, an inhibitor of glutamine synthetase, only cells that produce enough of the enzyme survive. The logic is straightforward: cells that have integrated more copies of the construct, or that express it more strongly, make more glutamine synthetase and therefore grow better under selection. Over time, this enriches the population for high-producing clones.

But the system has a well-known weakness, and it lies in the intrinsic biochemistry of glutamine synthetase itself. The protein is remarkably stable inside the cell, persisting long after it is made. That stability means that even cells with modest expression of the construct accumulate enough enzyme to survive selection. In practical terms, the selection stringency is low: the survival bar is easy to clear, and cells with suboptimal productivity slip through alongside the rare high performers. Traditional workarounds involve escalating concentrations of methionine sulfoximine or laborious rounds of gene amplification and clone screening, both of which add months to cell line development and introduce regulatory and manufacturing complexities. Methionine sulfoximine, after all, is a chemical inhibitor that must be rigorously controlled and eventually removed from the production process, and amplified gene copies can be unstable over long culture periods.

The Inha team approached the problem from an angle that has become increasingly fashionable in cell engineering: proteostasis, the tightly regulated balance between protein synthesis and protein degradation. Rather than trying to control how much glutamine synthetase mRNA is transcribed or translated, they attacked the protein itself, engineering variants that carry modular degrons, short peptide sequences that tag a protein for destruction by the cell’s own degradation machinery. By fusing these degrons to glutamine synthetase, the researchers created what they call destabilized GS, or dGS, variants that are actively and continuously broken down inside the cell. A cell can only maintain sufficient glutamine synthetase activity if it produces the protein at a very high rate, which in turn requires high expression of the linked construct. The degradation tag effectively raises the survival bar, making selection far more stringent without changing the selection conditions at all.

The researchers tested this concept in CHO cells engineered to express either a reporter protein or Etanercept, a fusion protein that combines an antibody fragment with a tumor necrosis factor receptor and is used to treat autoimmune conditions such as rheumatoid arthritis. When the standard, stable glutamine synthetase was used as the selection marker, the resulting cell pools showed the familiar pattern: a broad distribution of productivity, with many mediocre producers surviving selection. When the destabilized GS variants were used instead, the picture changed markedly. The dGS-selected pools were selectively enriched for cells with markedly enhanced productivity, demonstrating that accelerating protein turnover translates directly into stronger selection pressure. The effect worked across both the reporter system and the commercially relevant Etanercept construct, suggesting the strategy is general rather than product-specific.

Molecular analysis of the enriched pools revealed something particularly interesting about where the productivity gains came from. A common assumption in cell line development is that higher productivity comes from gene amplification, meaning the cells have acquired more copies of the therapeutic gene, often through selection regimes designed to force amplification. But when the team examined the dGS pools, they found that the improvements were driven primarily by increased per-copy mRNA abundance rather than by an increase in gene copy number. In other words, the cells that survived the stringent selection were not those with the most genes, but those that made the most messenger RNA from each copy they had. This distinction is significant for manufacturing, because per-copy expression efficiency can be more stable across long production runs than amplified gene arrays, which are prone to silencing or loss over time.

The performance numbers underscore the practical potential of the approach. The top-performing dGS pool achieved an Etanercept titer of 870 milligrams per liter in shake-flask batch culture, a respectable figure for a non-optimized, drug-free system that did not rely on extensive gene amplification. Equally important, the pool maintained stable production over 80 days of continuous passaging, indicating that the high-producing phenotype was not a transient artifact of selection but a durable property of the enriched cell population. Stability over weeks of culture is a critical requirement for commercial manufacturing, where a production campaign can run for many weeks and any decline in titer translates directly into lost product and higher costs. The fact that these results were obtained without chemical selection agents or amplification regimes suggests the method could simplify both the development timeline and the regulatory dossier for new biologic drugs.

The broader significance of the study lies in its demonstration that proteostasis engineering, the deliberate manipulation of protein degradation rates, can serve as a design tool for selection systems, not just as a way to study protein turnover. By choosing or tuning a degron, researchers can in principle dial in exactly how much of a survival protein a cell must produce to stay alive, converting a binary drug-based selection into a graded, high-stringency filter that favors the best producers. Because the strategy operates at the level of protein stability rather than transcription or translation, it is conceptually orthogonal to existing optimization approaches and could be combined with them. The authors suggest that this capability has the potential to accelerate cell line development and reduce manufacturing complexity in biopharmaceutical production, two goals that the industry pursues relentlessly given the enormous cost and time pressures of bringing a biologic to market.

There are, of course, questions that future work will need to address before degradable selection markers become standard practice in industrial cell line development. The study was conducted at shake-flask scale, and performance in the stirred-tank bioreactors used for commercial manufacturing will need to be confirmed. The long-term behavior of degron-tagged proteins under the metabolic stresses of large-scale culture, and the interaction of accelerated protein degradation with the cellular burden of producing a therapeutic protein at high levels, remain areas for further investigation. Nevertheless, the core result stands as a striking proof of concept: by making an essential enzyme deliberately fragile, the researchers turned the cell’s own protein quality control system into a powerful engine for finding its best producers. In an industry where every percentage point of titer improvement carries real economic weight, teaching selection systems to exploit proteostasis may prove to be one of the more consequential ideas to emerge from cell line engineering in recent years.

Subject of Research: Proteostasis engineering of glutamine synthetase for stringent, drug-free selection of high-producing Chinese hamster ovary cell lines

Article Title: Proteostasis engineering of glutamine synthetase for stringent, drug-free selection in Chinese hamster ovary cells

Article References: Kim, H., Park, J. U., Ha, J., & Baik, J. Y. (2026). Proteostasis engineering of glutamine synthetase for stringent, drug-free selection in Chinese hamster ovary cells. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-14015-5

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14015-5

Keywords: CHO cells, glutamine synthetase, proteostasis, degrons, protein degradation, selection stringency, cell line development, biopharmaceutical manufacturing, Etanercept, per-copy mRNA abundance, drug-free selection, protein stability